Boundless Bio, Inc. Common Stock
BOLDStock
$2.49+113.91%52W
Market Cap$55.29M
P/E—
Div yield—
Beta0.60
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)91.32%
Price vs S&P 500 (4W)76.11%
VGM Score87.89
Market Capitalization$55.29M
Earnings Surprise History
Q1 26-0.60est. -0.59
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.29
2.29
2.29
2.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BOLDBoundless Bio, Inc. Common Stock | — | — | A | $2.49 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Boundless Bio is a clinical-stage oncology company developing therapeutics that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification in cancer. The company's lead program, BBI-355, is an oral CHK1 inhibitor designed to disrupt ecDNA replication and transcription, addressing an unmet need in patients with oncogene-amplified tumors.